Finn
CAI Precision diagnostics · AI TechBio · Oncology · Growth · Thesis updated November 15, 2026

Caris pushes capacity as clinical testing volume accelerates

01 Running thesis

Scaling past breakeven

Caris is showing real scaling power. In Q3 2026, revenue rose 27 percent year over year to $275 million. The company marked its sixth straight quarter of positive adjusted EBITDA and management raised full year revenue guidance to over $1 billion.

The bull case rests on volume growth and new products. Clinical volume accelerated to 61,500 cases in the third quarter, up 21 percent year over year. The company also entered the monitoring market with Caris Assure Therapy Response Monitoring and plans to launch Caris Confirm for minimal residual disease in December 2026.

The bear case focuses on growing pains and cash burn. Near-term cash generation took a hit in Q3, with free cash flow dropping to a negative $39.7 million. Management made deliberate inventory investments to build capacity for the Caris Detect launch and prevent back orders.

The next clear watch items are the scaling pace for Caris Detect, the December rollout for Caris Confirm, and the expected interim readout for the ACHIEVE 2 study in the first quarter of 2027.

Nov 2026▲Q3 2026 clinical volume grew 21 percent to 61,500 cases, driving revenue up 27 percent to $275 million. The company raised full year guidance but posted negative free cash flow due to inventory investments for new product launches.
Aug 2026▲Q2 2026 revenue grew 45 percent year over year to $263.7 million. Management raised full year guidance to over $1 billion, driven by volume growth and the successful launches of Caris Detect and ChromoSeq.
May 2026▲Q1 2026 revenue rose 78.8 percent year over year to $216.2 million, and the net loss narrowed to $0.5 million. MI Cancer Seek raised average selling price, and a new financing deal added up to $1.2 billion of debt capacity.
Mar 2026▲FY 2025 revenue reached $812.0 million, up from $412.3 million, and Adjusted EBITDA improved to $137.7 million. The filing also added the expected 2026 launch of whole genome sequencing solutions as a catalyst.
Nov 2025▲Q3 2025 showed a profit milestone, with $24.3 million of net income and $51.2 million of Adjusted EBITDA on $216.8 million of revenue. This strengthened the case that the platform can scale.
Aug 2025▲The first public 10-Q after the June 2025 IPO set the baseline view. Revenue grew 81 percent year over year to $181.4 million, while the key risks centered on adoption and reimbursement for MI Cancer Seek and Caris Assure.
02 Business model

Tests first, data second

Caris makes most of its money by selling molecular profiling services. These tests read cancer samples from tissue or blood to help doctors pick treatments. In Q3 2026, molecular profiling services produced $262.7 million of revenue.

The second business sells pharma research and development services. Drug companies use Caris data, testing, and bioinformatics to study cancer and improve drug programs. This part of the business contributed $12.7 million in the third quarter.

The model works best when test volumes rise and each test earns strong reimbursement. The major risk is execution. If new products face manufacturing limits or back orders, revenue growth could stall even with high demand.

03 Product portfolio

A cancer testing stack

Cash cow

MI Profile

MI Profile is the tissue-based platform and generates most of the company revenue.

Growth engine

Caris Assure

Caris Assure is the universal blood-based profiling platform used for therapy selection.

Option

Caris Detect

Launched in June 2026, this multi-cancer early detection assay is a major catalyst but faces near-term capacity limits.

Option

Caris Confirm

A whole-genome minimal residual disease assay scheduled to launch in December 2026.

Option

ChromoSeq

Launched in April 2026, this therapy selection assay features whole genome and whole transcriptome technology.

Steady

Biopharma R&D services

Caris works with drug companies on testing, data, and discovery projects. This smaller business makes the data platform more valuable.

04 Business segments

Mostly clinical testing

Molecular profiling services96%growing fast
Pharma research and development services4%flat

The mix is from Q3 2026 revenue. Molecular profiling is the clear revenue base, so any reimbursement or capacity change in that line matters a lot.

05 Risk factors

What could break

Capacity constraints

High impact · Medium odds

Management noted that near-term demand for the newly launched Caris Detect could outstrip the rollout pace. The company spent heavily on inventory in Q3, driving free cash flow negative, but back orders remain a real risk.

We watchWatch inventory levels, capital spending, and free cash flow margins.

Reimbursement pressure

High impact · Medium odds

Higher reimbursement rates have helped lift the average selling price for older tests. If payers cut rates or limit coverage for new platforms like ChromoSeq, growth could slow even if test volume keeps rising.

We watchWatch average selling price comments, payer coverage updates, and molecular profiling revenue per case.

Debt-funded expansion misfires

Medium impact · Low odds

Caris has access to up to $1.2 billion in debt capacity. That gives it room to expand or buy assets, but it raises the cost of a bad deal if growth does not follow.

We watchWatch acquisitions, debt outstanding, and interest expense.
06 Quick answers

In one breath

What does Caris Life Sciences do?

Caris sells cancer molecular profiling tests. These tests study tumor tissue or blood so doctors can better match patients with treatments.

How does Caris make money?

Most revenue comes from molecular profiling services sold for clinical use. A smaller part comes from pharma research and development services, where drug companies pay for Caris testing and data.

Is Caris profitable?

The company reported its sixth consecutive quarter of positive adjusted EBITDA in Q3 2026. However, free cash flow turned negative recently as the company spent heavily to build inventory.

What is the biggest catalyst for CAI stock?

The clearest near-term catalysts are the scaling of the newly launched Caris Detect, the December 2026 launch of Caris Confirm for minimal residual disease, and trial readouts in 2027.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 15, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Caris Life Sciences Q3 2026 Earnings Transcript
  2. Caris Life Sciences Q2 2026 Form 10-Q
  3. Caris Life Sciences Q1 2026 Form 10-Q
08 Explore the industry

Comparable Biotechnology companies

Companies near Caris Life Sciences, Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today